Alkaline Phosphatase
Recombinant proteinexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 7, 2021 (NCT04923282)
Timeline
Indications
Mechanism of action
- Alkaline phosphataseSupplementation
Alkaline phosphatase supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594490 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06168799 | Phase 2 | Dec 20, 2023 | AM-Pharma, FGK Clinical Research GmbH, Radboud University |
| NCT05890794 | Phase 1/Phase 2 (Phase 2) | May 15, 2023 | AM-Pharma |
| NCT04923282 | Phase 1 | May 7, 2021 | AM-Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AM-Pharma | For profit | 3 | 3 | 2 | 2021 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2023 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1